Sonio Receives FDA 510(k) Clearance For Use of AI in Prenatal Ultrasounds
Sonio has received Regulatory Class II FDA 510(k) clearance for Sonio Detect, a manufacturer-agnostic software product that uses artificial intelligence (AI) to enhance the quality of fetal exams, and automatically detect views and quality criteria of ultrasound images.
In clinical testing, Sonio Detect’s software was found to have a high accuracy rate in identifying correct labels, views and quality criteria—regardless of manufacturers—as well as patient BMI, age, ethnicity and gestational age. Additionally, Sonio Detect was validated on over 17k ultrasound images, showing more than 92% sensitivity on its ability to detect labels and types of ultrasound images.
In real time, it automatically detects views, anatomical structures within supported views, and verifies quality criteria of the supported views, allowing healthcare professionals to quickly detect presence of heart and brain structures, and other important fetal imaging quality criteria.
“We are deeply committed to advancing the field of prenatal health through innovation at Sonio. Obtaining FDA clearance for our products demonstrates our dedication to safety and efficacy in the U.S. market. Our goal is to ensure everyone has access to top-quality prenatal care across the globe,” said Remi Besson, co-founder of Sonio.
Related Articles
-
The FDA has issued three new draft guidances related to the 510(k) submissions program, including Best Practices for Selecting a Predicate Device, Use of Clinical Data in Premarket Notification and Evidentiary Expectations for Implant Devices. The agency is accepting comments…
-
As VP of Product Marketing for a MedTech startup, my role is to champion pioneering medical technology, strategically spark interest and drive it out of the design lab and into the field where it will ultimately change, or even save…
-
Effective February 7, the agency will conduct inspections across all commodities, as well as mission-critical foreign and domestic inspections.
-
The draft guidance proposes updates to clarify how the Breakthrough Devices Program may be applicable to certain medical devices that promote health equity, as well as considerations in designating eligible devices that may benefit populations impacted by disparities in health…
